The value of providing quality-of-life information to managed care decision makers

Drug Benefit Trends

Volumn 13, Issue 7, 2001, Pages 45-52

  Crawford, B K ^a   Dukes, E M ^a   Evans, C J ^a  

^a MAPI VALUES   (United States)

Author keywords

Formularies; Managed care; Quality of life

Indexed keywords

DRUG;

ARTICLE; CAREGIVER; COST EFFECTIVENESS ANALYSIS; DECISION MAKING; DRUG EFFICACY; DRUG FORMULARY; DRUG PREFERENCE; DRUG SAFETY; EVALUATION; HEALTH CARE COST; HUMAN FACTORS RESEARCH; INSTRUMENT; MANAGED CARE; MANAGED CARE ORGANIZATION; MANAGER; MEDICAL INFORMATION; PATIENT ATTITUDE; PHARMACY; QUALITY OF LIFE; QUESTIONNAIRE; TELEPHONE;

EID: 0034925998     PISSN: 10805826     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (11)

1. Pharmaceuticals in Medicare reform
2. Managed care pharmacy, socioeconomic assessments and drug adoption decisions
3. The view from managed care pharmacy
4. The role of cost-effectiveness analysis in managed-care decisions
5. Hospital pharmacy decisions, cost containment, and the use of cost-effectiveness analysis
6. Reassessing the relevance of pharmacoeconomic analyses in formulary decisions
7. The role of pharmacoeconomic information in the formulary decision making process
8. The use of technology assessment by hospitals, health maintenance organizations, and third-party payers in the United States
9. Clinical improvement as reflected in measures of function and health related quality of life: Sensitivity and relative efficiency to detect a treatment effect in a 12-month placebo controlled trial comparing leflunomide with methotrexate
10. Patient-based measures of drug treatment in rheumatoid arthritis trials are not susceptible to placebo effect